隶属于 诺华制药
MorphoSys AG is a biopharmaceutical company dedicated to the discovery, development and commercialization of therapies for people living with cancer and autoimmune diseases. MorphoSys is advancing its own pipeline of new drug candidates and has created antibodies that are developed by partners in different areas of unmet medical need. Tremfya (guselkumab) - developed by Janssen Research & Development, LLC and marketed by Janssen Biotech, Inc. for the treatment of plaque psoriasis - became the first drug based on MorphoSys antibody technology to receive regulatory approval. The U.S. Food and Drug Administration granted accelerated approval of the company's proprietary product Monjuvi (tafasitamab-cxix) in combination with lenalidomide for patients with a certain type of lymphoma.
相关临床试验
71
56 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
1992
进行中（未招募）
56
78.9%
Approved For Marketing
1
1.4%
已完成
11
15.5%
招募中
1
1.4%
终止
1
1.4%
撤回
1
1.4%
暂无批准数据
- Actinium Pharmaceuticals has appointed Steffen Heeger, MD, MSc, as Chief Medical Officer, bringing extensive radiotherapy expertise and a track record of developing multiple oncology programs from preclinical through global approvals. - Dr. Heeger previously led clinical development of blockbuster drug Erbitux at Merck KGaA and served as CMO at NBE Therapeutics, which was acquired by Boehringer Ingelheim for $1.4 billion. - The appointment comes as Actinium prepares to advance its targeted radiotherapy pipeline, including Actimab-A, ATNM-400, and Iomab-ACT, toward key data readouts and expanded clinical trials in the second half of 2026. - Dr. Heeger's experience with anti-PSMA programs directly aligns with Actinium's ATNM-400 asset, which targets a novel antigen and has shown preclinical activity across multiple solid tumor indications.
- Biogen has acquired TJ Biopharma's exclusive rights to felzartamab in Greater China for up to $850 million, consolidating worldwide development and commercialization rights under one owner. - The CD38-directed monoclonal antibody is currently being evaluated in global Phase 3 trials for multiple immune-mediated diseases including IgA nephropathy and primary membranous nephropathy. - China represents a critical market opportunity with one of the largest patient populations globally for both IgA nephropathy and primary membranous nephropathy, two leading causes of kidney disease. - A Biologics License Application for felzartamab in multiple myeloma treatment is currently under review by China's National Medical Products Administration.
- Asgard Therapeutics has appointed Professor Dr. Wolfram Brugger as Chief Medical Officer to lead the clinical development of AT-108, a first-in-class gene therapy. - AT-108 represents a breakthrough "personalized off-the-shelf" immunotherapy that reprograms tumor cells into dendritic cells to trigger personalized immune responses against cancer. - Dr. Brugger brings extensive experience from over 130 Phase I-III oncology trials and successful drug development programs at AstraZeneca, MorphoSys, and Autolus Therapeutics. - The company is currently advancing IND-enabling studies for AT-108, with key proof-of-concept data published in Science journal in 2024.
- Tango Therapeutics appointed Dr. Malte Peters as President and CEO, replacing founding CEO Dr. Barbara Weber who transitions to Executive Chair. - The leadership change comes as the company's lead PRMT5 inhibitor vopimetostat prepares to enter registrational trials for pancreatic cancer in 2026. - Dr. Peters brings extensive late-stage clinical development experience, having previously led global regulatory approval of Monjuvi at MorphoSys AG. - The company maintains its 2026 clinical milestone guidance, including combination trial data and pivotal study initiation for vopimetostat.
- SOTIO Biotech has appointed Amy Jensen-Smith as Chief Scientific Officer and Ulrich Moebius as Chief Development Officer to strengthen its leadership team and advance its pipeline of antibody-drug conjugates and immunotherapies. - Dr. Jensen-Smith has been instrumental in developing SOTIO's lead preclinical ADC candidates SOT106 and SOT109, which target mesenchymal tumors and colorectal cancer respectively. - Dr. Moebius brings over 25 years of experience in drug development and previously served as SOTIO's chief of preclinical development from 2017 to 2024. - The appointments support SOTIO's focus on next-generation ADCs targeting solid tumors and its ongoing Phase 1 VICTORIA-01 study of SOT201 immunocytokine.
- Molecular Partners has appointed Martin Steegmaier, Ph.D. as Chief Scientific Officer effective October 1, 2025, bringing extensive oncology drug development experience from senior roles at Roche, MorphoSys, Boehringer Ingelberg, and SOTIO Biotech. - Steegmaier will lead the research organization and advance the company's pipeline of targeted DARPin therapeutics for cancer patients, including Radio-DARPins and Switch-DARPins for logic-gated immune cell activation. - The appointment strengthens Molecular Partners' leadership team as the clinical-stage biotech company continues developing its proprietary DARPin platform for medical challenges that other drug modalities cannot readily address. - Steegmaier previously served as CSO at SOTIO Biotech and Head of Research at MorphoSys, with particular expertise in antibody-based therapeutics in immuno-oncology and hematology-oncology.
- Vor Bio acquired exclusive global rights (excluding Greater China) to develop and commercialize telitacicept, a dual-target fusion protein approved in China for multiple autoimmune diseases including generalized myasthenia gravis. - The licensing agreement includes $125 million in initial payments to RemeGen, with potential regulatory and commercial milestones exceeding $4 billion plus tiered royalties. - Telitacicept demonstrated a 4.8-point improvement in MG-ADL scale versus placebo at 24 weeks in a Phase 3 trial in China, with global Phase 3 results expected in the first half of 2027. - Jean-Paul Kress, MD, was appointed as Vor Bio's new CEO and Chairman, bringing extensive pharmaceutical leadership experience from MorphoSys and other major companies.
- Maxion Therapeutics has appointed Dr. Stefan Härtle as Chief Development Officer, bringing nearly 20 years of pharmaceutical R&D experience to advance the company's KnotBody® platform into clinical trials. - Dr. Härtle previously served as Head of Clinical Pharmacology at MorphoSys and played key roles in developing approved antibody therapeutics including felzartamab and tafasitamab. - The appointment comes as Maxion prepares to advance its proprietary KnotBody® technology targeting ion channels and GPCRs for autoimmune conditions, chronic pain, and cardiovascular disease. - The company recently secured $72 million in Series A financing in March 2025 to support its pipeline development and platform advancement.
- Essential thrombocythemia affects approximately 167,000 individuals in the US as of 2024, with 75% of cases linked to JAK2 gene mutations and only one approved therapy currently available in Europe. - The market is projected to grow from $417 million in 2024 at a significant compound annual growth rate through 2034, driven by emerging therapies with novel mechanisms of action. - Several promising pipeline candidates are advancing through clinical trials, including Bomedemstat from Merck, ropeginterferon alfa-2b from PharmaEssentia, and Pelabresib targeting BET proteins. - Current treatment approaches rely on risk stratification, with low-risk patients receiving aspirin and high-risk patients managed with cytoreductive therapies like hydroxyurea.
- Johnson & Johnson's TREMFYA (guselkumab) achieved both primary and secondary endpoints in Phase 3b APEX study, demonstrating significant reduction in symptoms and structural damage progression in active psoriatic arthritis at 24 weeks. - As the first and only IL-23 inhibitor to show significant inhibition of structural damage, TREMFYA offers a crucial treatment option for patients at risk of irreversible joint damage who have not responded to standard therapies. - The dual-acting monoclonal antibody, which blocks IL-23 while binding to CD64 receptor, maintained its established safety profile with no new safety signals identified during the trial.
